Wide therapeutic time window for fasudil neuroprotection against ischemia-induced delayed neuronal death in gerbils

Brain Research

Volumn 1128, Issue 1, 2007, Pages 175-180

  Satoh, Shin ichi ^a   Toshima, Yoshinori ^a   Ikegaki, Ichiro ^a   Iwasaki, Masakazu ^a   Asano, Toshio ^a  

^a ASAHI KASEI PHARMA CORPORATION   (Japan)

Author keywords

Cerebral ischemia; Delayed neuronal death; Fasudil; Gerbil; Neuroprotection; Rho kinase

Indexed keywords

DRUG METABOLITE; FASUDIL; HYDROXYFASUDIL; NORPHENAZONE; OZAGREL; RHO KINASE INHIBITOR; SCAVENGER; THROMBOXANE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BRAIN ISCHEMIA; CIRCULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENCY; FOLLOW UP; GERBIL; MALE; NERVE CELL LESION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; ANTIPYRINE; CELL DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; FREE RADICAL SCAVENGERS; GERBILLINAE; ISCHEMIA; MALE; NEURONS; NEUROPROTECTIVE AGENTS; TIME FACTORS;

ANIMALIA; GERBILLINAE;

EID: 33846006516     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.10.027     Document Type: Article

References (38)

1. Arai M., Sasaki Y., and Nozawa R. Inhibition by the protein kinase inhibitor HA1077 of the activation of NADPH oxidase in human neutrophils. Biochem. Pharmacol. 46 (1993) 1487-1490
2. Asano T., Ikegaki I., Satoh S., Mochizuki D., Hidaka H., Suzuki Y., Shibuya M., and Sugita K. Blockade of intracellular actions of calcium may protect against ischaemic damage to the gerbil brain. Br. J. Pharmacol. 103 (1991) 1935-1938
3. Brabeck C., Mittelbronn M., Bekure K., Meyermann R., Schluesener H.J., and Schwab J.M. Effect of focal cerebral infarctions on lesional RhoA and RhoB expression. Arch. Neurol. 60 (2003) 1245-1249
4. Chrissobolis S., and Sobey C.G. Evidence that Rho-kinase activity contributes to cerebral vascular tone in vivo and is enhanced during chronic hypertension. Circ. Res. 88 (2001) 774-779
5. DeGracia D.J., and Montie H.L. Cerebral ischemia and the unfolded protein response. J. Neurochem. 91 (2004) 1-8
6. DeKeyser J., Sulter G., and Luiten P.G. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?. Trends Neurosci. 22 (1999) 535-540
7. Dyker A.G., and Lees K.R. Duration of neuroprotective treatment for ischemic stroke. Stroke 29 (1998) 535-542
8. Fellman V., and Raivio K.O. Reperfusion injury as the mechanism of brain damage after perinatal asphyxia. Pediatr. Res. 41 (1997) 599-606
9. Higashi M., Shimokawa H., Hattori T., Hiroki J., Mukai Y., Morikawa K., Ichiki T., Takahashi S., and Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo. Circ. Res. 93 (2003) 767-775
10. Hitomi A., Satoh S., Ikegaki I., Suzuki Y., Shibuya M., and Asano T. Hemorheological abnormalities in experimental cerebral ischemia and effects of protein kinase inhibitor on blood fluidity. Life Sci. 67 (2000) 1929-1939
11. 2α-induced contraction of rabbit aortae. J. Physiol. 546 (2003) 823-836
12. Kawaguchi A., Ohmori M., Harada K., Tsuruoka S., Sugimoto K., and Fujimura A. The effect of a Rho kinase inhibitor Y-27632 on superoxide production, aggregation and adhesion in human polymorphonuclear leukocytes. Eur. J. Pharmacol. 403 (2000) 203-208
13. Kirino T. Delayed neuronal death. Neuropathology 20 (2000) S95-S97
14. Lees K.R. Trends in protecting ischemic brain. In: Bogousslavsky J. (Ed). Acute Stroke Treatment. 2nd ed. (2003), Martin Dunitz, London
15. Maiese K., Wagner J., and Boccone L. Nitric oxide: a downstream mediator of calcium toxicity in the ischemic cascade. Neurosci. Lett. 166 (1994) 43-47
16. Meschia J.F., and Brott T.G. Reopening occluded cerebral arteries. In: Bogousslavsky J. (Ed). Acute Stroke Treatment. 2nd ed. (2003), Martin Dunitz, London
17. Miyagi Y., Carpenter R.C., Meguro T., Parent A.D., and Zhang J.H. Upregulation of rhoA and rho kinase messenger RNAs in the basilar artery of a rat model of subarachnoid hemorrhage. J. Neurosurg. 93 (2000) 471-476
18. Moonis M., and Fisher M. Combination therapies, restorative therapies and future directions. In: Bogousslavsky J. (Ed). Acute Stroke Treatment. 2nd ed. (2003), Martin Dunitz, London
19. Niggli V. Rho-kinase in human neutrophils: a role in signaling for myosin light chain phosphorylation and cell migration. FEBS Lett. 445 (1999) 69-72
20. Ohtaki M., and Tranmer B. Pretreatment of transient focal cerebral ischemia in rats with the calcium antagonist AT877. Stroke 25 (1994) 1234-1240
21. Phan T.G., Wright P.M., Markus R., Howells D.W., Davis S.M., and Donnan G.A. Salvaging the ischaemic penumbra: more than just reperfusion?. Clin. Exp. Pharmacol. Physiol. 29 (2002) 1-10
22. Plesnila N. Role of mitochondrial proteins for neuronal cell death after focal cerebral ischemia. Acta. Neurochir. 89 (2004) 15-19
23. Rikitake Y., Kim H., Huang Z., Seto M., Yano K., Asano T., Moskowitz M.A., and Liao J.K. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 36 (2005) 2251-2257
24. Sato M., Tani E., Fijikawa H., and Kaibuchi K. Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ. Res. 87 (2000) 195-200
25. Satoh S., Ikegaki I., Suzuki Y., Asano T., Shibuya M., and Hidaka H. Neuroprotective properties of a protein kinase inhibitor against ischaemia-induced neuronal damage in rats and gerbils. Br. J. Pharmacol. 118 (1996) 1592-1596
26. Satoh S., Kobayashi T., Hitomi A., Ikegaki I., Suzuki Y., Shibuya M., Yoshida J., and Asano T. Inhibition of neutrophil migration by a protein kinase inhibitor for the treatment of ischemic brain infarction. Jpn. J. Pharmacol. 80 (1999) 41-48
27. Satoh S., Utsunomiya T., Tsurui K., Kobayashi T., Ikegaki I., Sasaki Y., and Asano T. Pharmacological profile of hydroxyl fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci. 69 (2001) 1441-1453
28. Satoh S., Yamaguchi T., Hitomi A., Sato N., Shiraiwa K., Ikegaki I., Asano T., and Shimokawa H. Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur. J. Pharmacol. 455 (2002) 169-174
29. Shibuya M., Suzuki Y., Sugita K., Saito I., Susaki T., Takakura K., Nagata I., Kikuchi H., Takemae T., Hidaka H., and Nakashima M. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J. Neurosurg. 76 (1992) 571-577
30. Shibuya M., Hirai S., Seto M., Satoh S., and Ohtomo E. Effects of fasudil in acute ischemic stroke: Results of a prospective placebo-controlled double-blind trial. J. Neurol. Sci. 238 (2005) 31-39
31. 2+ sensitization in the bovine cerebral artery. Circ. Res. 91 (2002) 112-119
32. Stoll G., Jander S., and Schroeter M. Inflammation and glial responses in ischemic brain lesions. Prog. Neurobiol. 56 (1998) 149-171
33. Takemoto M., Sun J., Hiroki J., Shimokawa H., and Liao J.K. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 106 (2002) 57-62
34. Toshima Y., Satoh S., Ikegaki I., and Asano T. A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor. Stroke 31 (2000) 2245-2250
35. Tsuchiya M., Sako K., Yonemasu Y., and Asano T. The effects of HA1077, a novel protein kinase inhibitor, on reductions of cerebral blood flow and glucose metabolism following acute and/or chronic bilateral carotid artery ligation in Wistar rats. Exp. Brain Res. 97 (1993) 233-238
36. Worthylake R.A., Lemoine S., Watson J.M., and Burridge K. RhoA is required for monocyte tail retraction during transendothelial migration. J. Cell Biol. 154 (2001) 147-160
37. Yamamoto T., Yuki S., Watanabe T., Mitsuka M., Saito K., and Kogure K. Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia. Brain Res. 762 (1997) 240-242
38. Yrjanheikki J., Tikka T., Keinanen R., Goldsteins G., Chan P.H., and Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13496-13500